Production of novel recombinant anti-EpCAM antibody as targeted therapy for breast cancer.

Autor: Mirzaei R; Recombinant Proteins Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran., Shafiee S; Recombinant Proteins Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran., Vafaei R; Recombinant Proteins Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran; Department of Surgery and Radiology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran., Salehi M; Recombinant Proteins Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran., Jalili N; Recombinant Proteins Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran., Nazerian Z; Recombinant Proteins Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran., Muhammadnajad A; Cancer Biology Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, Iran., Yadegari F; Recombinant Proteins Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran., Reza Esmailinejad M; Department of Surgery and Radiology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran., Farahmand L; Recombinant Proteins Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran. Electronic address: laylafarahmand@gmail.com.

Publikováno v: International immunopharmacology [Int Immunopharmacol] 2023 Sep; Vol. 122, pp. 110656. Date of Electronic Publication: 2023 Jul 18.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.